KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Gross Profit (2016 - 2025)

Historic Gross Profit for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Regeneron Pharmaceuticals' Gross Profit rose 298.06% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.2 billion, marking a year-over-year increase of 66.64%. This contributed to the annual value of $13.2 billion for FY2025, which is 66.64% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Gross Profit stood at $3.6 billion for Q4 2025, which was up 298.06% from $3.5 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Gross Profit's 5-year high stood at $4.6 billion during Q2 2021, with a 5-year trough of -$178.0 million in Q4 2022.
  • In the last 5 years, Regeneron Pharmaceuticals' Gross Profit had a median value of $3.2 billion in 2023 and averaged $2.9 billion.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Gross Profit tumbled by 10670.65% in 2022 and then skyrocketed by 195187.54% in 2023.
  • Regeneron Pharmaceuticals' Gross Profit (Quarter) stood at $4.1 billion in 2021, then tumbled by 104.3% to -$178.0 million in 2022, then soared by 1884.1% to $3.2 billion in 2023, then increased by 9.03% to $3.5 billion in 2024, then increased by 2.98% to $3.6 billion in 2025.
  • Its Gross Profit was $3.6 billion in Q4 2025, compared to $3.5 billion in Q3 2025 and $3.4 billion in Q2 2025.